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Expediting rare disease diagnosis:
a call to bridge the gap between clinical
and functional genomics
Samantha N. Hartin1,2†, John C. Means1,2†, Joseph T. Alaimo1,2,3,4 and Scott T. Younger1,2,3,5*

Abstract
Approximately 400 million people throughout the world suffer from a rare disease. Although advances in whole
exome and whole genome sequencing have greatly facilitated rare disease diagnosis, overall diagnostic rates remain
below 50%. Furthermore, in cases where accurate diagnosis is achieved the process requires an average of 4.8 years.
Reducing the time required for disease diagnosis is among the most critical needs of patients impacted by a rare
disease. In this perspective we describe current challenges associated with rare disease diagnosis and discuss several
cutting-edge functional genomic screening technologies that have the potential to rapidly accelerate the process of
distinguishing pathogenic variants that lead to disease.
Keywords: Rare disease diagnosis, Functional genomics, Massively parallel genomic assays, Pooled CRISPR screening
Background
Approximately 400 million individuals worldwide are
directly affected by a rare disease (Wakap et al. 2019;
Global Genes:RARE Facts 2020). Roughly 70% of rare diseases are exclusively pediatric-onset and 30% of children
with a rare disease will not live to 5 years of age (Wakap
et al. 2019; Global Genes:RARE Facts 2020). At present,
the average time from disease onset to accurate diagnosis for a rare disease is 4.8 years (Global Genes:RARE
Facts 2020; Blöß et al. 2017). Reducing the time required
for disease diagnosis holds the promise of improving the
quality of life for rare disease patients and in some cases
may provide a window for therapeutic intervention that
would otherwise be missed.
Improved DNA sequencing technologies and decreases
in the cost of DNA sequencing have led to the routine use of whole exome sequencing (WES) and whole
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genome sequencing (WGS) in a clinical setting. While
the application of these technologies has greatly facilitated the identification of disease-associated genetic variants, the rate of diagnosis for rare disease remains below
50% (Soden et al. 2014; Yang et al. 2014; Lee et al. 2014).
Increased accessibility of DNA sequencing has also had a
pronounced impact on the field of functional genomics.
High-throughput sequencing-based assays have made it
possible to simultaneously profile the functional capacity
of thousands of DNA sequences in a single experiment
(Melnikov et al. 2012; Kheradpour et al. 2013). Despite
the inherent power of these experimental approaches,
their application in clinical settings have been limited.
Here we propose that high-throughput functional
assays capable of profiling the impact of clinically
detected genetic variants be implemented directly within
clinical genome sequencing centers. We provide an overview of several high-throughput assays, covering details
of their technical execution along with the practical limitations of each approach. Importantly, the techniques we
describe can be incorporated into most clinical sequencing platforms without the need to modify existing
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laboratory infrastructure. These powerful genomic
technologies have the potential to rapidly accelerate the
process of identifying genetic variants, particularly rare
variants, that are likely to be pathogenic and could dramatically reduce the amount of time required for rare
disease diagnosis.

The current state of rare disease diagnosis
In the United States a rare disease is defined as a condition that afflicts fewer than 200,000 individuals (Wakap
et al. 2019). Those impacted by a rare disease typically
harbor extremely rare, often de novo, genetic variants
that are not observed in the general population. The
clinical application of WES/WGS technologies has been
instrumental in improving the ability to detect these rare
variants and their use has doubled the number of Mendelian disease gene associations over the course of the
last ten years (Fernandez-Marmiesse et al. 2018). When
combined with variant interpretation guidelines outlined
by the American College of Medical Genetics (ACMG)
and the Association for Molecular Pathology (AMP)
these technologies routinely achieve diagnostic rates of
25–35% in pediatric cohorts with idiopathic disease(Yang
et al. 2014; Iglesias et al. 2014; Farwell et al. 2014; Hartman et al. 2019). Although these diagnostic rates are
encouraging, at present the majority of rare disease
patients that undergo WES/WGS remain undiagnosed.
Characterizing and categorizing genetic variants
identified through WES/WGS is a highly involved and
time-consuming process. The ACMG/AMP guidelines
recommend that variants be subjected to a comprehensive assessment that incorporates population frequency,
computational/predictive algorithms to infer effects of
variants on protein function, experimental evidence
with in vitro assays directly measuring variant function
or animal models mimicking phenotypic features, segregation analysis in multigeneration/offspring pedigrees,
variant origin/configuration, and additional information
or data from reputable sources (Richards et al. 2015). In
many cases there is insufficient data to satisfy these criteria and variants are categorized as variants of uncertain
significance (VUS). Large-scale data repositories such as
gnomAD and ClinVar that store and curate variant information have greatly assisted variant characterization
and reduced the levels of VUS reporting in recent years
(Hartman et al. 2019; Landrum et al. 2013, 2015, 2017;
Karczewski et al. 2020). However, these reductions have
not been accompanied by improved diagnostic rates indicating that alternative approaches to assess variant pathogenicity are needed (Hartman et al. 2019).
Among the most compelling lines of evidence to support variant pathogenicity is the presence of empirical data demonstrating the impact of a given variant on
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genome function. This data is particularly valuable for
noncoding variants as their functional consequences
are challenging to predict using existing computational
algorithms. However, empirical data for rarely observed
genetic variants is often nonexistent. Moreover, the time
and costs associated with performing detailed functional
studies for a large number of potentially pathogenic variants can be prohibitive. Advances in high-throughput
sequencing-based functional screening technologies (e.g.
massively parallel genomic assays, large-scale pooled
CRISPR screening) over the past several years now provide scalable mechanisms to assign functional properties to large catalogs of variants. These approaches can
be used to rapidly distinguish clinically detected variants
with an increased likelihood of pathogenicity and facilitate the prioritization of variants that warrant in-depth
evaluation.

Large‑scale variant profiling using massively
parallel genomic assays
One common experimental approach used to explore the
functional consequences of a genetic variant has been the
use of plasmid-based reporter assays. These assays can be
engineered to harbor specific variant sequences within
exons, introns, or even noncoding regulatory regions of
a transgenic reporter gene. Individual reporter constructs
can be introduced into cultured cells and transgene
expression and/or function can be evaluated using relevant methods. In recent years several plasmid-based
reporter approaches have been adapted to multiplexed
formats that permit the characterization of thousands of
genetic variants simultaneously using high-throughput
sequencing-based readouts. These massively parallel
genomic assays have been utilized to profile published
catalogs of disease-associated genetic variants and distinguish variants with functional implications (Tewhey
et al. 2016; Cheung et al. 2019). Incorporating these massively parallel genomic assays into clinical workflows has
the potential to significantly accelerate the process of pinpointing pathogenic variants.
Massively parallel genomic assays are performed with
diverse libraries of reporter constructs that are generated
through a combination of array-based DNA synthesis
and large-scale molecular cloning. In general, thousands
of 100 to 200 nt oligos containing genomic sequences
centered around variants-of-interest are designed and
synthesized. The resulting oligo pool is cloned directly
into a reporter construct that can subsequently be introduced into cultured cells. Several companies specializing
in oligonucleotide synthesis offer pooled oligo synthesis as a service and the process of library cloning can be
completed within a few days using basic molecular cloning techniques. At the completion of an assay RNA or
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DNA is harvested and the functional impact of each variant is determined by measuring the relative abundance of
individual library elements through targeted sequencing.
The vast majority of disease-associated genetic variants
occur in noncoding regions of the human genome (Hindorff et al. 2009; Gusev et al. 2014). Noncoding variants
located within functional regulatory elements that influence the expression of disease genes can be pathogenic
(Spielmann and Mundlos 2016). However, most noncoding variants occur in regions of the genome with no prior
functional annotation and predicting their pathogenicity
remains a major challenge. Massively parallel genomic
assays have provided a powerful platform for profiling the
impact of noncoding variants on the regulatory capacity
of genomic sequences. Briefly, these assays incorporate
variant-containing sequences upstream of a barcoded
reporter gene and high-throughput sequencing is used
to quantify barcode abundance as a proxy for the regulatory potential of the upstream sequence (Fig. 1a). These
expression assays have been used to profile thousands of
noncoding variants reported by the 1000 Genomes Project as well as variants identified through various GWAS
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studies (Tewhey et al. 2016; Ulirsch et al. 2016). We
propose that similar expression assays be implemented
within clinical sequencing platforms to profile clinically
detected variants. In our undiagnosed patient population at Children’s Mercy Kansas City we typically observe
several thousand "family-specific" rare variants and hundreds of “patient-specific" (de novo) rare variants per
individual, the majority of which occur within noncoding
regions of the genome. We’ve functionally profiled thousands of these variants using the approaches described
here resulting in the discovery of many variants located in
genomic regions proximal to disease-relevant genes that
have a significant impact on regulatory activity. Importantly, standard clinical practices would not have prioritized these particular variants for detailed investigation.
In Fig. 1b we show representative data for one such rare
variant that dramatically alters gene expression in our
reporter assays. This variant is located on chromosome
1, roughly 13 kb downstream of NHLH2 (Fig. 1c). The
NHLH2 gene encodes a transcription factor that directly
regulates expression of Prohormone Convertase 1/3, an
enzyme associated with dwarfism in mouse models (Zhu
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Fig. 1 Massively parallel genomic assays for profiling genetic variants. a Assay design for profiling the impact of genetic variants on gene
expression. b Representative experimental results for a rare genetic variant that alters gene expression in a reporter assay. c Genomic location of rare
variant profiled in (b). d Assay design for profiling the impact of genetic variants on RNA splicing. e Representative experimental results for a rare
genetic variant that alters exon inclusion in a splicing assay. f Genomic location of rare variant profiled in (e)
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et al. 2002; Fox and Good 2008). In agreement with these
models, the clinical features of the patient harboring this
particular variant include short stature, macrocephaly,
and mesomelic arm/leg shortening.
Genetic variants have also been shown to cause largeeffect disruptions in RNA splicing (Cheung et al. 2019).
However, most variants that disrupt splicing occur outside of canonical splice sites (Cheung et al. 2019). As a
result, these variants are difficult to predict based on
sequence alone and their identification requires experimental testing. Several different massively parallel
genomic assays have been designed to profile the impact
of genetic variants on RNA splicing. These assays typically incorporate variant-containing exons into a fixed
intronic region of a reporter gene and high-throughput
sequencing is used to evaluate inclusion/exclusion of
the exon (Fig. 1d). These splicing assays have been used
to profile variants cataloged in the Human Gene Mutation Database as well as variants identified through the
Exome Aggregation Consortium (ExAC) (Cheung et al.
2019; Soemedi et al. 2017). Collectively, these studies
have identified more than one thousand naturally occurring variants that significantly disrupt RNA splicing.
We propose that similar approaches be implemented to
profile the effect of clinically detected genetic variants
on splicing. Many of the rare variants we’ve identified
in our undiagnosed patients at Children’s Mercy Kansas
City occur within gene bodies (introns/exons) and are
not predicted to impact protein sequence or function.
We’ve functionally profiled hundreds of these variants
and identified dozens that significantly alter RNA splicing, bringing us a major step closer to determining which
of these variants may be pathogenic. In Fig. 1e we show
representative data for a rare variant that dramatically
alters exon inclusion in our splicing assays. This variant
is located on chromosome 2, within an intron of KIF5C
(Fig. 1f ). Previously reported variants in the KIF5C gene
have been associated with intellectual disability and epilepsy (Ligt et al. 2012; Poirier et al. 2013). Consistent with
these observations, the clinical features of the patient
harboring this particular variant include intellectual disability, seizures, and vision loss.
In contrast to current standard clinical approaches that
rely heavily on prior knowledge, the massively parallel
genomic assays discussed here provide a mechanism to
directly evaluate the functional consequences of variants
at the molecular level. However, these assays are plasmidbased and some variants may exhibit distinct functional
characteristics when profiled outside of their endogenous
genomic context. As a result, we anticipate that a subset of consequential variants may register as false negatives when using these techniques. Although the data
generated by these assays might not alone be sufficient
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to achieve a clinical diagnosis, the information they provide can be used to rapidly prioritize variants for followup validation and significantly reduce the time required
to illuminate those that are pathogenic. Importantly, the
infrastructure and equipment required to perform these
assays are already in place within clinical sequencing
centers. A typical assay profiling several thousand variants can be completed in less than one month for less
than $10 K, including sequencing costs.
Although massively parallel genomic assays have
proven to be powerful experimental tools, there are a
number of practical limitations that must be considered
prior to their implementation. For example, array-based
DNA synthesis is currently limited to oligo lengths under
200 nt which constrains the size of genomic regions that
can be profiled. In addition, the sequence composition of
some genomic regions may preclude DNA synthesis and/
or result in biases during the cloning process. Lastly, the
genomic background of the cell types in which assays are
performed can impact variant function. For this reason,
we recommend that assays are performed across a panel
of cell lines representing a diversity of cellular contexts.

High‑throughput variant characterization using
cell‑based phenotypic assays
Many genetic variants may lead to disease through mechanisms that are more complex than disruptions in basic
molecular processes (e.g. RNA splicing, direct transcriptional regulation). Distinguishing the functional consequences of these variants may require assays that are
capable of profiling cellular phenotypes. Advances in
genome editing technology, specifically CRISPR/Cas9,
have dramatically improved the ability to engineer cellular models with specific genetic alterations (Cong et al.
2013). Similar to the massively parallel genomic assays
described previously, many CRISPR-based approaches
have been adapted to multiplexed/pooled formats that
permit the functional screening of thousands of genetic
perturbations in parallel (Shalem et al. 2014). These
methods can be utilized to phenotypically profile the
consequences of clinically detected variants in highthroughput and dramatically improve the ability to discern variants that are likely to be pathogenic.
Pooled CRISPR-based screens are lentiviral-delivery
genetic assays that introduce a diversity of genetic perturbations into a large cell population (Shalem et al. 2014;
Piccioni et al. 2018). Libraries of oligos encoding sgRNAs
that target genomic sequences-of-interest are designed
and synthesized using array-based DNA synthesis. The
resulting oligo pool is cloned into a lentiviral backbone
that can be used to generate a complex pool of lentivirus. The pooled library virus is transduced into a large
Cas9-expressing cell population at a low multiplicity
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of infection such that the majority of infected cells harbor a single viral integrant. Following the application
of selective pressure (e.g. proliferation, differentiation)
genomic DNA is isolated from the remaining cell population and targeted sequencing of the viral cassette is used
to quantify sgRNA abundance as a proxy for the functional impact of the genetic perturbation. While pooled
CRISPR screening has proven to be a robust technology,
it does have practical limitations. For example, largescale pooled CRISPR screens can require hundreds of
millions of cells which may preclude the use of some cellular models. Furthermore, screens that require the isolation of cell populations with complex phenotypes may be
prohibitive.
Genome-wide pooled CRISPR screens have been
widely used to identify genetic dependencies in varied cellular models. The majority of these screens have
focused on the knockout (CRISPRko), inhibition (CRISPRi), or activation (CRISPRa) of protein-coding genes
(Shalem et al. 2014; Sanson et al. 2018). However, most
disease-associated variants occur within noncoding
regions of the genome (Gusev et al. 2014; Spielmann and
Mundlos 2016). Recently, several reports have described
the use of pooled CRISPR screening technologies to
identify essential noncoding regulatory elements in the
human genome (Korkmaz et al. 2016; Gasperini et al.
2016; Han et al. 2018; Borys and Younger 2020). These
approaches have utilized pooled CRISPR libraries that
target noncoding genomic regions-of-interest as opposed
to protein-coding genes (Fig. 2a). Representative data
from one of our CRISPRi-based pooled screens targeting putative noncoding regulatory elements are shown
in (Fig. 2b; Borys and Younger 2020). We find that this
approach is able to identify regulatory elements > 100 kb
from the nearest annotated gene that are essential for cell
proliferation. This same strategy can be applied to clinically detected genetic variants by perturbing genomic
regions that harbor these variants in cell-based models and evaluating the impact on cellular phenotypes
(Fig. 2a). Although this method does not model the exact
variants detected in patients, it can be used to illuminate
genomic regions that may be functionally implicated in
disease etiology.
Most CRISPR screens reported to date have utilized
cell-based models that have been highly optimized
to reflect specific biological contexts. However, undiagnosed rare diseases are often associated with an
array of clinical presentations and generating a cellbased model that can precisely reflect a large number
of patients is not feasible. For this reason, we propose
the use of generalized cell models that can be screened
to identify variant-harboring regions that are associated with frequently observed clinical features. For
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Fig. 2 Pooled CRISPR screening of genetic variants. a Design of an
sgRNA library for screening genetic variants. b Representative data
from a proliferation-based pooled CRISPR screen targeting putative
noncoding regulatory elements. A selection of sgRNAs targeting
common genomic sites have been labeled. c Frequency of clinical
presentations in our undiagnosed patient population. d Schematic of
pooled CRISPR differentiation screens

example, over 30% of the undiagnosed patient population at Children’s Mercy Kansas City have neurodevelopmental challenges, 8% are impacted by skeletal
abnormalities, and 5% have cardiovascular complications (Fig. 2c). We have implemented a pooled CRISPRi/CRISPRa screening strategy in which iPSCs are
transduced with variant-targeting CRISPR libraries
and subsequently differentiated into relevant cell types
(e.g. neurons, osteoblasts, cardiomyocytes) (Fig. 2d).
The enrichment/depletion of sgRNAs in differentiated
cells can be used to pinpoint genomic regions that are
likely to be associated with disease-related phenotypes.
Once these regions are identified, iPSC lines harboring
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individual clinically detected variants can be engineered to more precisely model disease biology.
The CRISPR screening approach we describe here is a
robust and efficient way to screen thousands of genetic
variants for potential roles in disease-related phenotypes.
Moreover, the use of CRISPR technology enables the perturbation of variant-containing sites in an endogenous
genomic context. As with the massively parallel genomic
assays discussed previously, pooled CRISPR screens do
not require specialized laboratory equipment and can
readily be performed in most clinical sequencing centers.
Experiments designed to screen several thousand variants can be completed in less than two months for less
than $15 K, including sequencing costs.
Pooled CRISPR screening will be particularly useful
for profiling the functional implications of noncoding
genetic variants. However, the current state of large-scale
CRISPR screening technology is limited to random indel
mutations (CRISPRko) or the repression/activation of
targeted genomic regions (CRISPRi/CRISPRa). Consequently, these screens do not perfectly model the impact
of clinically detected variants. As CRISPR-based screening methods continue to advance it may become possible
to functionally screen large numbers of specific variants
through pooled format adaptations of precision editing
technologies (e.g. base editing, search-and-replace editing) (Shen et al. 2018; Anzalone et al. 2019).

Conclusions
The ability to rapidly assign experimentally determined
functional properties to clinically detected genetic variants will have profound impacts on rare disease diagnosis. In addition to existing resources, clinical geneticists
will have access to empirical data that will facilitate more
informed decisions related to variant pathogenicity. This
information will reduce the time required to analyze individual patient genomes, increase patient throughput, and
ultimately translate to improved rates of diagnosis. Moreover, the barriers to generating this data are minimal as
many high-throughput functional assays do not require
modifications to existing laboratory infrastructure nor do
they require patient specimens.
The experimental strategies we discuss here are
intended to complement, not replace, current standard practices in variant interpretation. Moreover, the
functional assays we have described are mainly suited
for Mendelian diseases. Experienced clinical geneticists
will always be needed to critique experimental results
and to investigate diseases with more complex genetic
contributions. Rare disease diagnosis will remain a constant challenge, but bridging the gap between clinical and
functional genomics could provide an accelerated path
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to diagnosis for many rare disease patients that are still
searching for answers.
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